OTCMKTS:PKPH Peak Pharmaceuticals (PKPH) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free PKPH Stock Alerts $5.50 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$5.50▼$5.5050-Day Range$1.12▼$5.5552-Week Range$0.52▼$9.12Volume10 shsAverage Volume9,053 shsMarket Capitalization$2.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsStock AnalysisChartFinancialsSEC Filings Get Peak Pharmaceuticals alerts: Email Address Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Peak Pharmaceuticals Stock (OTCMKTS:PKPH)Peak Pharmaceuticals, Inc. manufactures and markets pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp for the prevention and alleviation of various conditions and diseases. The company was founded on December 18, 2007 and is headquartered in Scottsdale, AZ.Read More PKPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PKPH Stock News HeadlinesMarch 5, 2024 | marketwatch.comAkari Therapeutics Signs Merger-of-Equals with Peak BioMarch 5, 2024 | markets.businessinsider.comAkari Therapeutics, Peak Bio Announces Agreement To Merge As Equals - Quick FactsApril 25, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…January 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Longboard Pharmaceuticals Amid Strong Bexicaserin Phase 2 Results and Blockbuster Revenue PotentialJune 14, 2023 | dailymail.co.ukPeak Practice is axedMay 31, 2023 | benzinga.comPeak Pharmaceuticals & Retrieve Medical Announce Signed Contract with Regional Medical CenterMay 31, 2023 | finance.yahoo.comPeak Pharmaceuticals & Retrieve Medical Announce Signed Contract with Regional Medical CenterMay 2, 2023 | usnews.comPeak to Peak Charter SchoolApril 25, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 28, 2023 | finance.yahoo.comPeak Pharmaceuticals Merges with Retrieve Medical, Inc.February 23, 2023 | seekingalpha.comPKPHD Peak Pharmaceuticals, Inc.February 14, 2023 | finance.yahoo.comPeak Pharmaceuticals Announces One-for-Two-Hundred Reverse Stock SplitFebruary 14, 2023 | finanznachrichten.dePeak Pharmaceuticals, Inc.: Peak Pharmaceuticals Announces One-for-Two-Hundred Reverse Stock SplitFebruary 1, 2023 | seekingalpha.comMirum Pharmaceuticals: In The Spotlight Following Buyout Of Albireo PharmaJanuary 30, 2023 | cnbc.comBMO says this stock taking gene therapy to the 'next level' can more than doubleJanuary 10, 2023 | msn.comShould You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?November 29, 2022 | cnbc.comHorizon Therapeutics fields buyout interest from Amgen, J&J and SanofiOctober 15, 2022 | seekingalpha.comPKPH Peak Pharmaceuticals, Inc.October 3, 2022 | reuters.comPeak Pharmaceuticals IncJune 14, 2022 | benzinga.comCannabis And PsychedelicsSeptember 9, 2021 | benzinga.comGood News For NY Cannabis Market Though Sales Won't Start Until 2023 Amid Regulatory UncertaintySeptember 9, 2021 | benzinga.comAUDACIOUS Teams Up With Professional Bull Riders On New CBD ProductsAugust 8, 2021 | benzinga.comGoing To Space Isn't The Only Way Jeff Bezos Wants To Get HighAugust 6, 2021 | barrons.comPeak Pharmaceuticals Inc.July 23, 2021 | benzinga.comNew York State Senator Aims To Speed Up Legal Cannabis Program Launch With New Cultivation BillSee More Headlines Receive PKPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Peak Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryCannabis Current SymbolOTCMKTS:PKPH CUSIPN/A CIK1452804 Webwww.peakpharma.com Phone(480) 659-6404FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-159.55% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares392,000Free Float320,000Market Cap$2.16 million OptionableNot Optionable Beta0.54 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesNeil ReithingerDirector, Chief Executive & Financial OfficerKey CompetitorsSalarius PharmaceuticalsNASDAQ:SLRXNotable LabsNASDAQ:NTBLVG Life SciencesOTCMKTS:VGLSCNS PharmaceuticalsNASDAQ:CNSPDermata TherapeuticsNASDAQ:DRMAView All Competitors PKPH Stock Analysis - Frequently Asked Questions How have PKPH shares performed in 2024? Peak Pharmaceuticals' stock was trading at $1.73 on January 1st, 2024. Since then, PKPH shares have increased by 217.9% and is now trading at $5.50. View the best growth stocks for 2024 here. What other stocks do shareholders of Peak Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Peak Pharmaceuticals investors own include CNBX Pharmaceuticals (CNBX), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), Medical Marijuana (MJNA), Organigram (OGI), Auxly Cannabis Group (CBWTF), GB Sciences (GBLX), GreenGro Technologies (GRNH), KushCo (KSHB) and MariMed (MRMD). How do I buy shares of Peak Pharmaceuticals? Shares of PKPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PKPH) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Peak Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
